Skip to main content

Table 2 Baseline characteristics of HIV infected children in HIV clinic at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia from April 1 to May 15, 2018 (n = 318).Baseline characteristics of

From: Predictors of treatment failure, time to switch and reasons for switching to second line antiretroviral therapy in HIV infected children receiving first line anti-retroviral therapy at a Tertiary Care Hospital in Ethiopia

Variables N (%)
Age years (at the time of cART initiation)
  ≤ 11 months 91(28.6)
 12 to 34 months 63(19.8)
 35–59 months 52(16.4)
  ≥ 60 months 112(35.2)
Initial HAART Regimen
 D4T-3TC-NVP 59(18.5)
 D4T-3TC-EFV 17(5.3)
 AZT-3TC-NVP 103(32.3)
 AZT-3TC-EFV 53(16.6)
 TDF-3TC-EFV 26(8.1)
 AZT-3TC-LPV/r 10(3.1)
 ABC-3TC-LPV/r 6(1.5)
 ABC-3TC-EFV 23(7.2)
 D4T-3TC-LPV/r 21(6.6)
Initial cART dosing preparations
 One loose 94(29.6)
 Three loose 81(25.5)
 Fixed 143(45)
PMTCT Service
 Present 21(6.6)
 None 237(74.5)
 Unknown 60(18.8)
Infant ART Prophylaxis
 Yes 37(11.6)
 No 235(73.8)
 Unknown 56(17.6)
Baseline Immunosuppression level
 Not Significant Immunosuppression (≥  500 or > 25%) 3(0.94)
 Mild Immunosuppression (350–499 or 20–24%) 23(7.2)
 Advanced Immunosuppression (200–349 or 15–19%) 137(43.08)
 Severe Immunosuppression (< 200 or < 15%) 155(48.74)
Base line WHO staging
 Stage 1 26(8.17)
 Stage 2 109(34.3)
 Stage 3 155(48.7)
 Stage 4 28(8.8)